Philips buys China's No 2 in patient monitoring for Asian expansion:
This article was originally published in Clinica
In a move to broaden its presence in the Chinese healthcare market, Philips has acquired China's second largest patient monitoring company, Shenzhen Goldway Industrial. Goldway's range of FDA-cleared and CE-marked patient monitors helped the company grow its sales by 30% in 2007. The 290-strong company has a distribution network that serves mid- and large-sized hospitals throughout China, according to Philips. On completion of the transaction, which is expected in the second quarter of 2008, Goldway will become part of Philips Healthcare's patient monitoring division.
You may also be interested in...
Finance Watch: LSP Dementia Fund Closes With €260m For Neurodegenerative Diseases
EQT Life Sciences completed the final close of its inaugural LSP Dementia Fund, far surpassing an initial $100m fundraising goal. Also, Resilience received a $410m commitment from the Department of Defense to fund biomanufacturing and Viking cashed in on Phase I obesity data with a $250m offering.
Bayer Relates Feeling ‘Sexy’ To Quick Relief For Allergies In Astepro Allergy Ad Campaign
Campaign featuring actress Meghann Fahy says "allergy sufferers can relieve their allergy symptoms and be more spontaneous in their romantic pursuits.” Ads launch two months after FDA granted tentative approval for two ANDAs for generic equivalents, indicating approval could come pending resolution of patent litigation.
Keytruda, Opdivo May Be Only Part B Drugs Chosen For Medicare Negotiation In First Applicable Year
In general, more Part D drugs will be eligible than Part B drugs in the early years of the program because Part D drugs have higher levels of spending and so will dominate the list of candidates. A new report sizes up the drugs that would qualify for Medicare Price negotiation in 2026-2028.